Table 4.
Treatment response and length of hospital stay after treating with different TANDEM size or doxorubicin-loading dose.
| Clinical outcomes | Total (n = 87) | TANDEM size | Doxorubicin loading | ||||
|---|---|---|---|---|---|---|---|
| 75 μm (n = 26) | 100 μm (n = 61) | P-valuea | Half-loaded (n = 15) | Full-loaded (n = 72) | P-valuea | ||
| Treatment response | 0.602 | 0.021 | |||||
| CR | 23 (26.4%) | 7 (26.9%) | 16 (26.2%) | 8 (53.3%) | 15 (20.8%) | ||
| PR | 32 (36.8%) | 11 (42.3%) | 21 (34.4%) | 3 (20.0%) | 29 (40.3%) | ||
| SD | 18 (20.7%) | 6 (23.1%) | 12 (19.7%) | 4 (26.7%) | 14 (19.4%) | ||
| PD | 14 (16.1%) | 2 (7.7%) | 12 (19.7%) | 0 (0.0%) | 14 (19.4%) | ||
| Length of hospital stay (days) | 3.4 ± 2.2 | 2.8 ± 1.9 | 3.7 ± 2.3 | 0.023 | 1.7 ± 1.4 | 3.8 ± 2.2 | < 0.001 |
Tumor response was evaluated 3 months after TACE treatment.
CR complete response, PR partial response, SD stable disease, PD progressive disease.